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Background: EBP50 and NHERF2 adaptor proteins are incriminated in various signaling pathways of the cell. They
can bind ERM proteins and mediate ERM-membrane protein interactions.
Results: Binding of ERM to EBP50 and NHERF2 was compared in pulmonary artery endothelial cells by
immunoprecipitation. NHERF2 associates with all three ERM, but EBP50 appeared to be a weak binding partner if at
all. Furthermore, we detected co-localization of NHERF2 and phospho-ERM at the cell membrane and in the
filopodia of dividing cells. Silencing of NHERF2 prevented agonist or angiogenesis induced phosphorylation of ERM,
while overexpression of the adaptor elevated the phosphorylation level of ERM, likely catalyzed by Rho kinase 2,
which co-immunoprecipitated with NHERF2/ERM in control EC, but did not bind to ERM in NHERF2 depleted cells.
Dependence of ERM phosphorylation on NHERF2 was also shown in Matrigel tube formation assay, and NHERF2
was proved to be important in angiogenesis as well. Furthermore, when NHERF2 was depleted or cells were
overexpressing a mutant form of NHERF2 unable to bind ERM, we found attenuated cell attachment with ECIS
measurements, while it was supported by overexpression of wild type NHERF2.
Conclusions: Pivotal role of NHERF2 in the phosphorylation process of ERM in pulmonary artery endothelial cells is
shown. We propose that NHERF2 provides a common anchoring surface for ERM and Rho kinase 2. Our results
demonstrate the essential role of NHERF2 in endothelial cell adhesion/migration and angiogenesis.
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The Na+/H+ exchanger regulatory factor (NHERF) family
consists of four scaffolding proteins, namely, NHERF1/
EBP50, NHERF2/E3KARP, NHERF3/PDZK1, and NHERF4/
IKEPP. They contain two or four PDZ domains which
serve as protein-protein interacting sequences [1]. So
far, NHERF proteins were mainly investigated in polarized
epithelial cells. These studies revealed different locations
and different protein binding partners of the members
of the family [2,3]. Besides playing an essential role in
the regulation of Na+/H+ exchanger-3 (NHE3), there is
a growing body of evidence that NHERF proteins are
implicated in many signaling pathways of the cell [4,5].
NHERF1/EBP50 and NHERF2 are similar proteins with
57% amino acid identity and they have the same domain
structure [6,7]. Although they have two PDZ domains,
they differ from the other members of the NHERF family* Correspondence: csortos@med.unideb.hu
Department of Medical Chemistry, University of Debrecen Medical and
Health Science Center, Egyetem tér 1, Debrecen H-4032, Hungary
© 2013 Boratkó and Csortos; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.by having a C-terminal ezrin/radixin/moesin (ERM) binding
domain/tail. An important difference between these proteins
is that EBP50 is a phosphoprotein. For example, it can be
phosphorylated during mitosis by cyclin dependent kinase
1 at two serine residues (Ser279 and Ser301) [8-11], how-
ever, NHERF2 does not contain these phosphorylation sites,
and phosphorylation of NHERF2 has not been reported
yet. Both EBP50 and NHERF2 were described as essential
components in the NHE3/ezrin/cAMP dependent protein
kinase II multiprotein signaling complex which is required
for the inhibition of ion transport via the phosphorylation
of NHE3 [12,13]. NHERF2 binds to an internal domain in
the cytoplasmic tail of NHE3, and it was suggested that by
binding to ezrin, it brings the cAMP dependent protein
kinase close enough to the cytoplasmic tail of NHE3, which
can be phosphorylated at elevated cAMP levels [7]. A more
recent study performed on NHERF2 knockout mice shows
that NHERF2 is necessary for normal basal trafficking of
NHE3, furthermore, cAMP inhibition and lysophosphatidic
acid (LPA) stimulation are NHERF2 dependent. It is alsoCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 EBP50 and NHERF2 have distinct interacting partners in
EC. (A) EBP50 or NHERF2 was immunoprecipitated from lysates of
BPAEC cells. Total cell lysate (input) and IP complexes were probed for
ERM, EBP50 and NHERF2 specific antibodies. (B) Anti-c-myc antibody
was utilized for immunoprecipitations form pCMV-myc ezrin (EZR),
pCMV-myc radixin (RDX) or pCMV-myc moesin (MSN) transfected
BPAEC cell lysates as described in Methods. Total cell lysates (input)
and IP complexes were probed for c-myc tag, EBP50 and NHERF2. Ø
AB: control of IP from BPAEC without the addition of antibody. Shown
are representative data of at least 3 independent experiments.
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in NHE3 regulation are organ and tissue specific [14].
Further binding targets of EBP50 and NHER2 are receptors,
scaffolding- and various signaling proteins as reviewed by
Shenolikar et al. [15].
ERM proteins are regulated linkers between the plasma
membrane and the actin cytoskeleton. They can bind
directly to adhesion molecules, but their interaction
with membrane proteins can be mediated by adaptor
proteins, such as the above mentioned EBP50 and NHERF2
[16]. ERM proteins have similar domain structures, they
share an N-terminal FERM domain and the F-actin
binding site is in their C-terminal ERM-associated domain
(C-ERMAD) [17]. Activation of the ERM proteins is phos-
phorylation dependent. The head-to-tail intramolecular
interaction of inactive ERMs is disrupted by the phosphor-
ylation of a conserved C-terminal threonine residue and
the N- and C-terminal domains become available for inter-
molecular interactions [18,19]. Cell type specific expression
of EBP50, NHERF2 and ERM seems to be parallel with
the binding preference between the NHERF and ERM
proteins [20].
NHERF proteins are less characterized in endothelial
cells (EC). Recently, we have shown nuclear localization
of EBP50 in the interphase in bovine pulmonary artery
endothelial cells (BPAEC) and in HUVEC [21]. During
mitosis, phosphorylation and cytoplasmic localization of
EBP50 was detected. Furthermore, protein-protein inter-
action and co-localization with protein phosphatase 2A
(ABαC) in mitotic BPAEC have been shown. ECIS (electric
cell-substrate impedance sensing) measurements proved
that the phosphorylated form of EBP50 supports EC wound
healing, suggesting the significance of EBP50 in cell division
[21]. Others described NHERF2 as a participant in endo-
thelial homeostasis and vascular remodeling [5].
In the present work binding ability of EBP50 and
NHERF2 to ERM was compared in pulmonary artery EC.
We show evidence that NHERF2 aids filopodia formation
and migration of EC by mediating phosphorylation of
ERM by Rho kinase 2 (ROCK2). Our results also indicate
that NHERF2 is required for proper EC tube formation.
Results
Endothelial EBP50 and NHERF2 have different ERM
binding capability
Earlier, we detected both EBP50 and NHERF2 proteins
in endothelial cells, however, our results indicated their
different subcellular localization, nuclear and cytoplasmic,
respectively, in interphase EC [21]. That suggests diverse
functions and protein partners of the two adaptors in EC.
EBP50 and NHERF2 proteins are known to interact with
ERM, as they have ERM binding tails at their C-termini.
To study whether endothelial ERM have any distinction
between these two adaptor proteins, immunoprecipitationexperiments were performed. Endogenous EBP50 and
NHERF2 were immunoprecipitated from bovine pulmon-
ary artery EC (BPAEC) lysates and the IP complexes were
probed in Western blot with an anti-ERM antibody. As
shown in Figure 1A, ERM proteins preferred to bind
NHERF2. To decide whether all three ERM are able to
bind to NHERF2, mammalian expression constructs were
created. BPAEC monolayers were transfected with expres-
sion constructs of ezrin, radixin, or moesin, each cloned
into pCMV-myc vector. Lysates of the overexpressing cells
were subjected to immunoprecipitation with anti-c-myc
antibody. Total cell lysates, to confirm the overexpression
of ezrin, radixin, or moesin, and the IP complexes were
tested in Western blot with monoclonal anti-c-myc,
EBP50 and NHERF2 antibodies. While EBP50 was not
detectable in these IP samples, the endogenous NHERF2
co-immunoprecipitated with each of the recombinant ERM
proteins (Figure 1B). Therefore we have focused our further
investigation on the ERM-NHERF2 interaction.
Phospho-ERM binds to NHERF2
Protein-protein interaction of NHERF2 and the phos-
phorylated form of ERM proteins was analyzed by
Figure 3 Phospho-ERM co-immunoprecipitates with NHERF2
from mitotic EC. NHERF2 was immunoprecipitated from lysates of
BPAEC without or with nocodazole (ND) treatment as described in
Methods. Cell lysates (input) and IP complexes were probed for ERM,
phospho-ERM and NHERF2. Shown are representative data of at least
3 independent experiments.
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with anti-phospho-ERM and anti-NHERF2 antibodies.
Nuclei were visualized by TO-PRO-3 Iodide. We observed
co-localization of the two proteins in the cell membrane
and filopodia of dividing cells at all phases of mitosis
(Figure 2). These results imply that NHERF2 may bind
to phospho-ERM proteins during mitosis.
Next, cells were arrested in G2/M phase by 80 ng/ml
nocodazole treatment for 16 h to induce phosphorylation
of ERM in large number of the cells, and then NHERF2
was immunoprecipitated. Lysates of control and noco-
dazole treated cells as well as the IP complexes were
probed with antibodies against ERM, phospo-ERM and
NHERF2 in Western blot (Figure 3). Indeed, the noco-
dazole challenge increased the phosphorylation level of
ERM compared to the asynchronized cells. In addition,
greater amount of phospho-ERM was detected in NHERF2
immunoprecipitates after nocodazole.
NHERF2 mediates phosphorylation of ERM through
interaction with ROCK2
To check the possible regulatory role of NHERF2 adaptor
protein in ERM phosphorylation, NHERF2 (SLC9A3R2)
was depleted in BPAEC cells using specific silencing RNA
duplexes. Five different siRNAs against NHERF2 were
tested, and the two most efficient ones (sc-42522 and
SI03084977) were used. The efficiency of depletion was
checked by Western blot (Figure 4A). Silencing of NHERF2
did not change the protein level of EBP50 (Figure 4A).Figure 2 Co-localization of phospho-ERM and NHERF2 during mitosis
using anti-phospho-ERM (red) and anti-NHERF2 (green) primary antibodies.
staining. Scale bars: 10 μm. Shown are representative data of at least 3 indeLysates of control, non silencing RNA and NHERF2-
specific silencing RNA transfected cells without or with
nocodazole treatment were analysed by Western blot
using antibodies against phospho-ERM, ERM, NHERF2,
and actin (Figure 4B and Additional file 1: Figure S1).
The phosphorylation level of ERM was about the same in
control and non silencing RNA transfected cells without
additional effector, and it increased to the same extent
after the nocodazole treatment. More importantly, the
phosphorylation level of ERM was extremely low in
NHERF2 depleted cells and did not increase in dividingin BPAEC. Immunofluorescence staining of BPAEC was performed
Phases of the cell cycle were identified using TO-PRO-3 Iodide
pendent experiments.
Figure 4 ERM cannot be phosphorylated in the absence of NHERF2. (A) Lysates of non transfected (ctr), non-siRNA or NHERF2 specific siRNA
(sc-42522) treated cells were analyzed by Western blot using anti-EBP50, -NHERF2 and -actin antibodies. (B) Lysates of non transfected (ctr),
non-siRNA or NHERF2 specific siRNA (sc-42522) treated cells without or with nocodazole (ND) challenge were analyzed by Western blot using
antibodies against phospho-ERM, ERM, NHERF2 and actin as described in Methods. (C) NHERF2 or ROCK2 was immunoprecipitated from lysates
of BPAEC. The IP complexes were probed for ROCK2 and NHERF2. (D) ROCK2 was immunoprecipitated from lysates of control, non-siRNA or
NHERF2 specific siRNA treated cells. IP complexes were probed for ROCK2, ERM and NHERF2. Shown are representative data of at least 3
independent experiments.
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Additional file 2: Figure S2). These results imply that
the adaptor protein is a necessary factor for ERM
phosphorylation.
One reasonable explanation of this observation can be
that NHERF2 provides a common binding surface for both
the ERM and the protein kinase which phosphorylates
ERM. The increase in phosphorylation level of ERM evoked
by nocodazole was significantly attenuated in the cells
which were pretreated with H1152 to inhibit ROCK2
(not shown). To further test this hypothesis, Rho kinase 2
(ROCK2) and NHERF2 were immunoprecipitated from
BPAEC lysates and in fact, both ROCK2 and NHERF2
were present in the two immunoprecipitates (Figure 4C).
Furthermore, we could detect ERM and NHERF2 in
ROCK2 IP complexes from control and non-siRNA
transfected EC, but the ERM was not present in the
ROCK2 immunoprecipitate from NHERF2 depleted cells
(Figure 4D) suggesting the plausibility of our assumption.
NHERF2 aids EC filopodia formation and cell spreading
In accordance with the above observations, NHERF2
overexpression increased the phosphorylation level of
ERM. The entire coding region of NHERF2 was amplified
by RT-PCR and it was cloned into a pCMV-HA vector.
Another construct, producing a truncated mutant form
of NHERF2, was also created. The mutant misses the
C-terminal ERM-binding tail, therefore it is not able to bind
to ERM. BPAEC were transfected with these constructs,and the effects of the overexpressed proteins on phospho-
ERM level were analyzed by Western blot. Overexpression
of wild type (wt) NHERF2 resulted in an increased
phosphorylation level (about 50% increase) of ERM, while
the mutant NHERF2 lacking the ERM-binding domain
did not trigger a significant increase in that (Figure 5A).
Immunofluorescent staining revealed that cells overex-
pressing wtNHERF2 show strong filopodia formation com-
pared to non-overexpressing EC, or cells transfected
with the mutant NHERF2 and the recombinant NHERF2
co-localizes with phospho-ERM (Figure 5B).
As filopodia play a role in cell migration and adhesion, to
monitor cell spreading and attachment ECIS measurements
were utilized. Sufficient number of EC transfected with
wt- or mutant NHERF2 were plated onto 8W10E arrays
24 h post-transfection to form confluent monolayers and
the resistances of the ECIS electrodes were followed in
time. The more rapid spreading dynamics of wtNHERF2
overexpressing cells compared to the control or mutant
NHERF2 overexpressing cells is clearly apparent (Figure 5C,
left panel). In a parallel ECIS experiment, non-siRNA and
NHERF2-specific siRNA transfected EC were compared.
As expected, the barrier formation of NHERF2 depleted
cells was slower than that of for the non siRNA treated
cells (Figure 5C, right panel).
NHERF2 affects EC tube formation
Endothelial cell migration and proliferation are essential
in angiogenesis. Therefore, based on the above results,
Figure 5 NHERF2 overexpression induces EC filopodia formation and spreading. (A) Lysates of BPAEC without transfection (ctr) or
transfected with pCMV-HA wild type or mutant NHERF2 constructs were analyzed by Western blot using antibodies against phospho-ERM, ERM,
and HA-tag. A representative Western blot is shown. Protein levels were quantified by densitometric analysis. Phospho-ERM protein levels were
normalized against ERM protein levels. Bars represent mean ± SE. Significant changes, determined by Student’s t-test, are indicated by asterisks;
**(P < 0.01), n = 6. (B) Left panel: Immunofluorescent staining of recombinant wild type or mutant NHERF2 overexpressing BPAEC was performed
using anti-HA primary antibody (green). Actin microfilaments were stained with Texas Red conjugated phalloidin (red). Scale bars: 10 μm. Right
panel: Wild type NHERF2 transfected BPAEC co-stained for phospho-ERM and HA-tag is shown. Arrows indicate co-localization of phosho-ERM
and overexpressed NHERF2 on the merged image. (C): Non transfected (control), wild type (wt) and mutant (mu) NHERF2 transfected cells
(left panel) or non-siRNA and NHERF2 specific siRNA treated cells (right panel) were plated onto 8W10E arrays. Spreading and attachment of cells
were followed in time by ECIS measurement. Results are presented as means ± SD at least of four chambers for each sample.
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ylation level of ERM proteins, NHERF2 plays a regulatory
role in angiogenesis. Control, non-siRNA- and NHERF2-
specific siRNA transfected EC were seeded on μ-Slide
plates coated with Matrigel. These tube formation assays
were monitored for 8 h with a light microscope. Control
cells started to form polygon structures at about 3 h after
seeding, and the network formation reached a peak at 5 h.
Silencing of NHERF2 inhibited the network formation and
resulted in formation of cell aggregates in the Matrigel
(Figure 6A). Next, ERM and phospho-ERM levels in lysates
of control, non-siRNA- and NHERF2-specific silencing
RNA transfected cells - seeded onto Matrigel - were ana-
lyzed before and during the course of the tube formationassays (Figure 6B). The phosphorylation level of ERM
proteins increased greatly in control and non-siRNA
treated cells without any change in the ERM protein
level. In contrast, the phosphorylation level of ERMs in
NHERF2 silenced cells could not change. Our results
indicate that NHERF2 is a crucial component in EC tube
formation by supporting the phosphorylation process of
ERM.
Discussion
Regulation of endothelial cytoskeleton structure remodeling
is essential in angiogenesis and in development and
maintenance of vascular barrier; and eventually, in proper
lung function. ERM are actin-binding linkers connecting
Figure 6 NHERF2 is required for EC tube formation. (A)
Control, non-siRNA or silencing RNA specific for NHERF2
transfected BPAEC were seeded on Matrigel-coated μ-Slide plates.
F-actin staining was done at 5 h after seeding, and images were
captured by confocal microscopy. Silencing of NHERF2 inhibits
cord formation, resulting in the formation of cell aggregates in
the Matrigel. (B) Western blot analysis of ERM and phospho-ERM
in control, non-siRNA or NHERF2 specific silencing RNA
transfected BPAEC grown in Matrigel and processed at 0, 2 and
4 h after seeding.
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ectly via adaptor proteins. NHERF scaffolding proteins are
known to be regulators of NHE3 in epithelial cells, but they
are also common interacting partners of ERM proteins
[1,15,22,23]. Based on the primary sequence and the do-
main structure, NHERF1/EBP50 and NHERF2/E3KARP
are the most similar members of the family [6,7,22], both
proteins have two PDZ domains and an ERM binding
domain at their C-termini. Previously, we have shown
cell-cycle and phosphorylation dependent localization
of EBP50 in EC in the nucleus [21], NHERF2, on the
other hand, did not appear in the nuclei of the immuno-
stained EC. The present work indicates that ERM binds
preferentially NHERF2 over EBP50 in EC. It was reported
that in HUVEC cells NHERF2 but not EBP50 is highly
expressed [5]. However, we cannot explain the difference
with lower protein level of EBP50, as semiquantitative as-
sessment of our RT-PCR products produced with EBP50
and NHERF2 specific oligonucleotide primers indicated
similar expression levels of the two adaptors in pulmonary
artery EC (data not shown). These results suggest that
NHERF2 has not only different binding partners, but
also its function(s) can be unlike that of EBP50 in EC.
Studies of NHERF localizations and functions in other
cell types also demonstrated such diversity. EBP50, for
instance, is the most enriched in tissues with extensive,
polarized epithelia and it is localized in cell surface
microvilli. ERM and EBP50 were reported to co-localize
in the cell surface, preference for ERM-EBP50 interaction
depending on tissue and cell type was also proposed [22].
Cell type specific appearance was observed in kidney cells,EBP50 being abundant in proximal tubule cells, while
NHERF2 was detected in the glomerulus [2]. Another
work also claims tissue-specific expression of the two
adaptor proteins and suggests EBP50-ezrin vs NHERF2-
moesin/radixin pairing [20]. Our studies with the pulmon-
ary artery EC did not indicate distinct abundancy of the
two adaptors or pairing among EBP50 or NHERF2 and the
individual ERM proteins. However, our findings imply that
NHERF2 is the preferred partner of ERM over EBP50.
Therefore, major part of this work was focused on the
investigation of the NHERF2-ERM complex in pulmonary
aorta EC. We found that phospho-ERM and NHERF2
co-localize at the cell membrane and in the filopodia in
dividing EC, moreover, phospho-ERM was present in
NHERF2 IP. ERM and NHERF2 are known to bind and
bring together membrane and non-membrane proteins,
providing structural links and organizing proteins, and
that may result in their involvement in several signal
transduction pathways. Role of ERM in RhoA, PKA, insu-
lin, or membrane receptor signaling, development, differen-
tiation, migration etc. have been reported [24-26]. Various
binding partners of NHERF2 including virulence factors,
Map, EspI and NleH1 [27], EPI64, a microvillar protein
[28], LPA2 receptor [29], or β-catenin [30] advocate broad
functions of the adaptor beside the regulation of NHE3.
Our results suggest that the ERM/NHERF2 protein-protein
interaction may have an importance in the phosphorylation
process of ERM, and consequently, NHERF2 can be signifi-
cant in cytoskeleton remodeling of EC. Both depletion and
overexpression of NHERF2 proved the above assumption.
When NHERF2 was silenced, nocodazole treatment could
not evoke ERM phosphorylation; on the other hand, over-
expression of NHERF2 increased the phospho-ERM level.
Ezrin, radixin and moesin are activated by phosphoryl-
ation of a threonine residue (T576, T564, T558, respect-
ively) [25]. Several kinases can phosphorylate ERM on this
threonine, including ROCK2 [18,25]. Our results imply
that NHERF2 is a key player in ERM phosphorylation
by presenting binding surface for ERM and ROCK2.
Although it is not completely clear yet whether both ERM
and ROCK2 bind directly to NHERF2, one may assume
attachment of ERM to the C-terminal ERM binding do-
main of NHERF2. Direct contact between NHERF2 and
the kinase cannot be excluded based on our results.
ROCK2 contains a pleckstrin-homology like (PH) domain
[31] which may interact with one of the PDZ domains
of NHERF2 [32]. The SRL amino acid sequence at the
N-terminal part of the PH domain in ROCK2 fits a recog-
nition motif, S/T-X-I/V/L, reported for NHERF2, although
this motif is usually positioned at the C-terminal of the
PDZ-binding peptide [29,33]. Although further research
is required to elucidate this suggestion, our finding
that ERM was not present in ROCK2 IP from NHERF2
depleted cells fits into this concept.
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ERM phosphorylation level and enhanced filopodia for-
mation. A relevant finding of Gandy et al. [34] indicates a
similar linkage between ERM phosphorylation and filopodia
formation in HeLa cells. Moreover, Theisen et al. [30]
showed that HT1080 fibrosarcoma cells expressing a
PDZ-domain mutant form of NHERF2 have reduced
lamellipodia and impaired cell migration, indicating the
substantial regulatory role of NHERF2 in cell migration.
An interesting study of Bhattacharya et al. [5] on HUVEC
reports an increase in endothelial proliferation after
NHERF2 knockdown and a critical role of NHERF2 in
endothelial homeostasis. Nevertheless, it has to be noted
that in our experiments overexpression or silencing of
NHERF2 in pulmonary artery EC did not cause detectable
change in the proliferation rate of cells. This indicates
the possibility of an altering role of NHERF2 in different
endothelial cell types.
Our results demonstrate that EBP50 and NHERF2 not
only have different localizations in vascular endothelial
cells, but they have differing functions in these cells as
well. In the NHERF2 depleted cells the protein level of
EBP50 did not increase which could be the sign of
substitution in function, instead, we observed alterations
in phospho-ERM level and filopodia formation during
mitosis. Therefore we suggest that NHERF2 is an essential
binding partner of ERM that aids phosphorylation of ERM
and eventually is involved in the arrangement/rearrange-
ment of plasma membrane-ERM-actin bridges during
filopodia formation and cell division. EBP50, on the other
hand, may have other binding partner(s) in the nuclei of
these cells and it may contribute in the transfer of those
partner(s) to cytoplasmic locations, cytoskeletal elements
during mitosis. Similarly, while there is an overlap in the
binding partners of EBP50 and NHERF2 in epithelial cells
like NHE3, there are also evidences indicating their unique
specificity for protein partners and cellular functions
[14,35]. Interestingly, although an increase of NHERF2
protein level in EBP50(−/−) kidney membrane fraction
was observed, still, the ERM/P-ERM level was decreased
in the membrane suggesting the pivotal role of EBP50 in
organizing apical epithelial membranes [36].
The effects of NHERF1 and 2 knockouts were studied
on epithelial cells in relation to the intestinal ion transport
by Seidler’s group [37-39]. They report different roles of
EBP50 and NHERF2 in regulating cystic fibrosis transmem-
brane conductance regulator (CFTR). Recent studies of
Song et al. [40,41] describe effects of EBP50 knockout
on migration and proliferation of vascular smooth muscle
cells. They suggest that EBP50 is a key regulator of vascular
remodeling as they found EBP50 to be required in neoin-
tima formation following endoluminal injury in mice.
We investigated the possible involvement of NHERF2
in major physiological functions of EC. ERM proteinsparticipate in cell adhesion and migration [24,42], which
are key components of barrier formation and angiogenesis.
Our results point to the critical role of phosphorylation of
ERM aided by NHERF2 in cell adhesion and migration, as
cell spreading and attachment of barrier forming EC was
attenuated in NHERF2 depleted cells or mutant NHERF2
(without the ERM binding domain) overexpressing EC.
On the other hand, overexpression of wild type NHERF2
resulted in a faster cell spreading compared to the controls.
Furthermore, NHERF2 may affect angiogenesis as well,
as we have shown that the polygonal network formation
of NHERF2 depleted cells in Matrigel was inhibited.
Our results imply the role of ROCK2 in these processes.
Participation of ROCK activity in endothelial barrier
maintenance was reported earlier in connection with the
EC junctions [43]. They claim that ROCK has a dual role
in regulation of EC barrier function, a protective activity
at the cell margins and a barrier-disruptive activity at
contractile F-actin stress fibers. It is also important to
note that ezrin hyperphosphorylation was found to cor-
relate with invasiveness of HCC (hepatocellular carcinoma),
and inhibition of ROCK activity reduced ezrin phosphoryl-
ation and resulted in a blockade to HCC cell invasion
[44]. Together with our new results it raises the question
whether NHERF2, as a modulator of ERM phosphoryl-
ation via ROCK2, may affect invasiveness of carcinoma
cells.
Conclusions
In summary, NHERF2 is the preferred ERM-binding
partner over EBP50 in pulmonary aorta EC. Our results
advocate the existence of an NHERF2-ERM-ROCK2 link-
age which seems to be critical in filopodia formation and
cell spreading, and consequently in EC barrier formation
and angiogenesis.
Methods
Reagents
Materials were obtained from the following sources: Ezrin/
Radixin/Moesin antibody, Phospho-Ezrin (Thr567)/Radixin
(Thr564)/Moesin (Thr558) antibody, HA-tag rabbit mAb,
ROCK2 rabbit mAb, anti-rabbit IgG HRP-linked and
anti-mouse IgG HRP-linked secondary antibodies: Cell
Signaling Technology, Inc. (Beverly, MA); anti-NHERF2
(C-2) antibody: Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA); anti-SLC9A3R1 antibody (NHERF1/EBP50): Abgent
(San Diego, CA); monoclonal anti-c-myc antibody: Zymed
Laboratories (South San Francisco, CA); Alexa 488-, Alexa
594-conjugated secondary antibodies and ProLong Gold
Antifade medium with DAPI: Molecular Probes (Eugene,
OR), Protease Inhibitor Cocktail Set III: EMD Biosciences
(San Diego, CA); pCMV-HA and pCMV-myc vectors:
Clontech Laboratories, Inc. (Mountain View, CA). Sub-
stances for cell culturing were from PAA (Austria).
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cals were obtained from Sigma (St Louis, MO).
Cell cultures
Bovine pulmonary artery endothelial cells (BPAEC) (culture
line-CCL 209) were obtained frozen at passage 8 (American
Type Tissue Culture Collection, Rockville, MD), and were
utilized at passages 15–20. Cells were maintained at 37°C
in a humidified atmosphere of 5% CO2 and 95% air in
MEM supplemented with 10% (v/v) heat inactivated
fetal bovine serum, 1% sodium pyruvate, 0.1 mM MEM
non-essential amino acids solution.
Preparation of vector constructs
The coding region of NHERF2 (NM_001077065.1), ezrin
(NM_003379.4), radixin (NM_002906.3), moesin (NM_002444)
and neurofibromin2 (NM_000268.3) was amplified by RT-
PCR using the following primers. Ezrin forward: 5′-AAG
AATTCCCATGCCGAAACCAATCAA-3′, reverse: 5′-G
GCTCGAGTTACAGGGCCTCGAA-3′; radixin forward:
5′-TCGTCGACCATGCCGAAACCAATCAACGT-3′, re-
verse: 5′-TATGCGGCCGCTCACATTGCTTCAAACTC
AT-3′; moesin forward: 5′- AAGAATTCCCATGCCCAA
AACGATCAGT-3′, reverse: 5′- GGCTCGAGTTACATA
GACTCAAATTCGTC-3′; NHERF2 wild type forward:
5′-GAGAATTCTTATGGCCCGCTCTGGGAAT-3′, re-
verse: 5′-TCCTCGAGTCAGAAGTTGCTGAAGATCT
C-3′; NHERF2 mutant forward: 5′-GAGAATTCTTATG
GCCCGCTCTGGGAAT-3′, reverse: 5′-AACTCGAGCT
ACTGAAAAGGATCTCGCTTCC-3′. All primers were
synthesized by Integrated DNA Technologies (Coralville,
IA). The PCR products were subcloned into pCMV-myc
(ERM) or pCMV-HA (NHERF2) mammalian expression
vectors using restriction sites created by the PCR primers.
The DNA sequences of the constructs were confirmed by
sequencing (Clinical Genomics Center, MHSC, RCMM,
University of Debrecen).
Transfection, siRNA silencing
BPAEC cells were transfected with pCMV-myc ezrin,
pCMV-myc radixin, pCMV-myc moesin or pCMV-HA
NHERF2 wild type and mutant plasmids using Lipofecta-
mine 2000 transfection reagents (Invitrogen Corporation,
Carlsbad, CA), according to the manufacturer’s instructions.
After 24 hours cells were washed and lysed.
NHERF2 (SLC9A3R2) was silenced using 25 nM
NHERF2 specific siRNA (sc-42522 from Santa Cruz or
SI00068376, SI00068383, SI03075562 and SI03084977
from Qiagen) in complex with DharmaFECT-1 transfection
reagent (Dharmacon) in serum-free medium. ON-TAR-
GETplus siCONTROL nontargeting pool (D-001810-
10-01-05; Dharmacon) was used as an irrelevant control.
After 6 h the medium was changed to complete medium.
Cells were further incubated for 48–72 hours. The twomost efficient siRNA (sc-42522 and SI03084977) were
used.Immunofluorescence and microscopy
Cells were grown on glass coverslips, washed once with
1X TBS and fixed with 3.7% paraformaldehyde in 1X TBS
for 10 min. Between each step, the cells were rinsed three
times with 1X TBS. All steps were performed at room
temperature. The cells were permeabilized with 0.5%
Triton X-100 in TBS for 15 min, blocked with 2% BSA
in TBS for 30 min, and incubated with primary, then
with secondary antibodies diluted in blocking solution
for 1 h. Coverslips were rinsed and mounted in ProLong
Gold Antifade medium. Confocal images were acquired
with an Olympus Fluoview FV1000 confocal microscope
using UPLSAPO 60x 1.35 NA oil immersion objective
on an inverted microscope (Olympus IX81) or with a
Leica TCS SP8 confocal microscope using HC PL APO
CS2 63x 1.40 NA oil immersion objective on an DMI6000
CS microscope at 25°C. Images were processed using
FV10-ASW v1.5 or LAS AF v3.1.3 software. Nonspecific
binding of the secondary antibodies was checked in control
experiments (not shown).Immunoprecipitation
Cells (~1×107) grown in 10 cm Ø dishes were rinsed three
times with 1x PBS and then collected and lysed with
600 μl of immunoprecipitation (IP) buffer (20 mM Tris
HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM sodium
vanadate, 1% Nonidet P-40) containing protease inhibitors.
The lysates were centrifuged with 10,000 g for 15 min at
4°C. To avoid nonspecific binding, the supernatants
were precleared with 50 μl of protein G Sepharose (GE
Healthcare, Piscataway, NJ) at 4°C for 3 h with end-over-end
rotation. Protein G Sepharose was removed by centrifuga-
tion at 4°C for 10 min, and the supernatant was incubated
with the appropriate volume of antibody (5 μg) at 4°C for
1 h and then with 50 μl of fresh protein G Sepharose at
4°C overnight with gentle rotation. The resin was washed
three times with 300 μl of IP buffer and then resuspended
in 150 μl of 1X SDS sample buffer, boiled, and micro-
centrifuged for 5 minutes. The supernatant (20 μl) was
further analyzed by Western blot.Western blotting
Protein samples (20 μg total protein each) were separated
by SDS-PAGE and transferred to 0.45 μm pore sized
Hybond ECL Nitrocellulose Membrane (GE Healthcare,
Piscataway, NJ). Western blots were imaged using an Alpha
Innotech FluorChem® FC2 Imager or Kodak Medical X-ray
Developer.
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ECIS (Electric cell-substrate impedance sensing) model Zθ,
Applied BioPhysics Inc. (Troy, NY) was used to monitor
spreading and attachment of control or transfected cells
seeded on type 8W10E arrays.
In vitro tube formation assay
BD Matrigel™ Basement Membrane Matrix (BD Biosci-
ences) was used to study the effect of NHERF2 silencing
on BPAEC capillary tube formation in accordance with the
manufacturer’s instructions. Control, non silencing RNA or
NHERF2-specific siRNA treated BPAEC (~1 × 103cells)
were plated in μ-Slide (Ibidi, Germany) previously coated
with Matrigel and incubated in triplicates at 37°C. Samples
were fixed with 2% paraformaldehyde for 10 min, perme-
abilized with 0.5% Triton-X for 20 min and blocked with
2% BSA in TBS for 20 min. Each step was made at room
temperature. CF594 conjugated phalloidin (Biotium, Inc.
Hayward, CA) was used to visualize actin filaments.
Representative photomicrographs of tube formation from
each group were captured by Leica TCS SP8 microscope
using HC PL FLUOTAR 10x 0.30 NA objective.
Additional files
Additional file 1: Figure S1. Lysates of non transfected (ctr), non-siRNA
or NHERF2 specific siRNA (SI03084977) treated cells without or with
nocodazole (ND) challenge were analyzed by Western blot using antibodies
against phospho-ERM, ERM, NHERF2 and actin as described in Methods.
Additional file 2: Figure S2. Non silencing RNA or NHERF2 specific
siRNA transfected BPAEC cells were immunostained with anti-NHERF2
(green) and anti-phospho-ERM (red) antibodies. Nuclei were visualized
using TO-PRO-3-Iodide.
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